150 related articles for article (PubMed ID: 28027454)
1. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers.
Vranic S; Feldman R; Gatalica Z
Bosn J Basic Med Sci; 2017 Feb; 17(1):9-11. PubMed ID: 28027454
[TBL] [Abstract][Full Text] [Related]
2. The role of histopathologic testing on apocrine carcinoma of the breast.
Ilhan B; Emiroğlu S; Türkay R; Ilhan R
Curr Probl Cancer; 2020 Apr; 44(2):100501. PubMed ID: 31521370
[TBL] [Abstract][Full Text] [Related]
3. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
4. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast.
Vranic S; Gatalica Z
Clin Breast Cancer; 2022 Jun; 22(4):e576-e585. PubMed ID: 35027319
[TBL] [Abstract][Full Text] [Related]
5. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
D'Arcy C; Quinn CM
J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous and mammary apocrine carcinomas have different immunoprofiles.
Piris A; Peng Y; Boussahmain C; Essary LR; Gudewicz TM; Hoang MP
Hum Pathol; 2014 Feb; 45(2):320-6. PubMed ID: 24342430
[TBL] [Abstract][Full Text] [Related]
7. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Vranic S; Marchiò C; Castellano I; Botta C; Scalzo MS; Bender RP; Payan-Gomez C; di Cantogno LV; Gugliotta P; Tondat F; di Celle PF; Mariani S; Gatalica Z; Sapino A
Hum Pathol; 2015 Sep; 46(9):1350-9. PubMed ID: 26208846
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.
Sasahara M; Matsui A; Ichimura Y; Hirakata Y; Murata Y; Marui E
Anticancer Res; 2014 Mar; 34(3):1261-7. PubMed ID: 24596370
[TBL] [Abstract][Full Text] [Related]
10. Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours.
Schmitt FC; Soares R; Seruca R
Virchows Arch; 1998 Dec; 433(6):505-9. PubMed ID: 9870682
[TBL] [Abstract][Full Text] [Related]
11. ER-α36, a novel isoform of ER-α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast.
Vranic S; Gatalica Z; Deng H; Frkovic-Grazio S; Lee LM; Gurjeva O; Wang ZY
J Clin Pathol; 2011 Jan; 64(1):54-7. PubMed ID: 21045236
[TBL] [Abstract][Full Text] [Related]
12. Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer.
Liu X; Yang Y; Feng X; Shen H; Liu J; Liu X; Niu Y
Oncotarget; 2016 Aug; 7(31):48905-48917. PubMed ID: 27340922
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
14. Apocrine gland carcinoma of the mammary skin concomitant with pagetoid phenomenon.
Usui K; Ochiai T; Abe I; Nishio H; Togo K; Yamagata M
J Dermatol; 2010 Apr; 37(4):350-4. PubMed ID: 20507405
[TBL] [Abstract][Full Text] [Related]
15. Intracytoplasmic lipid accumulation in apocrine carcinoma of the breast evaluated with adipophilin immunoreactivity: a possible link between apocrine carcinoma and lipid-rich carcinoma.
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Shiraiwa M; Nishida C; Morita T; Sato Y; Hayashi T; Kato A
Am J Surg Pathol; 2011 Jun; 35(6):861-7. PubMed ID: 21566511
[TBL] [Abstract][Full Text] [Related]
16. FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.
Gromov P; Espinoza JA; Talman ML; Honma N; Kroman N; Timmermans Wielenga V; Moreira JM; Gromova I
PLoS One; 2014; 9(11):e112024. PubMed ID: 25389781
[TBL] [Abstract][Full Text] [Related]
17. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
Shim HS; Jung WH; Kim H; Park K; Cho NH
APMIS; 2006 May; 114(5):352-8. PubMed ID: 16725011
[TBL] [Abstract][Full Text] [Related]
18. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
20. Mixed pleomorphic lobular and apocrine carcinoma of the breast: A case report suggesting pathogenesis.
Ishii A; Oishi T; Kakuda Y; Yasui H; Kawata T; Muramatsu K; Takahashi K; Sugino T
Pathol Int; 2019 May; 69(5):288-293. PubMed ID: 30811750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
